GlassScriptPhysician profile
Shipra Prasad
NPI 1346849700
$2,889.07
in general payments reported to CMS, 2019-2025
33 companies · $731 in 2025
The $731 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $251 · 2022: $611 · 2023: $694 · 2024: $603 · 2025: $731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,679 · Education: $348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,678.66 |
| Education | $348.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $380.78 | 2022-2024 | Xtandi, Padcev |
| Amgen INC. | $311.54 | 2022-2023 | Kyprolis, Lumakras, Nplate |
| Incyte Corporation | $256.13 | 2021-2024 | Jakafi |
| Pharmacosmos Therapeutics INC. | $230.17 | 2022-2025 | Monoferric |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $225.66 | 2024-2025 | Lifevest |
| Cvrx, INC. | $172.93 | 2025 | Barostim Neo System |
| Eisai INC. | $171.55 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $132.51 | 2021-2025 | Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $131.67 | 2022-2024 | Iclusig |
| Janssen Biotech, INC. | $111.62 | 2022-2024 | Tecvayli, Talvey, Darzalex |
| Regeneron Healthcare Solutions, INC. | $83.93 | 2023-2025 | Libtayo |
| Atricure, INC. | $68.74 | 2024 | |
| Gilead Sciences, INC. | $60.36 | 2021-2023 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $53.15 | 2022-2024 | |
| Taiho Oncology, INC. | $52.06 | 2024-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $49.50 | 2024 | |
| Novartis Pharmaceuticals Corporation | $47.33 | 2023 | |
| Abbvie INC. | $43.83 | 2023 | |
| Seagen INC. | $32.73 | 2023 | Padcev |
| Glaxosmithkline, LLC. | $28.54 | 2023 | Jemperli, Zejula |
| Medicomp INC | $28.43 | 2025 | Telepatch Cardiac Monitor |
| Lilly USA, LLC | $27.74 | 2022-2023 | Jaypirca, Verzenio |
| Philips North America LLC | $26.30 | 2025 | Lm Undivided |
| Aveo Pharmaceuticals, INC. | $21.71 | 2023 | Fotivda |
| Dendreon Pharmaceuticals LLC | $19.07 | 2024 | Provenge |
| Cordis US Corp. | $18.58 | 2024 | Mynx Venous Vcd |
| Puma Biotechnology, INC. | $16.57 | 2024 | |
| Octapharma USA, INC. | $16.34 | 2024 | Octagam Immune Globulin (Human) |
| Astrazeneca Pharmaceuticals LP | $15.47 | 2024 | |
| Daiichi Sankyo INC. | $15.40 | 2022 | |
| Celgene Corporation | $14.06 | 2023 | Opdualag |
| Global Blood Therapeutics, INC. | $13.38 | 2022 | |
| Sanofi Pasteur INC. | $11.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shipra Prasad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.